This study is testing a new drug called DCSZ11, both by itself and in combination with other approved cancer treatments like pembrolizumab, doxorubicin, or tebentafusp. It's for people with advanced or metastatic (spread throughout the body) solid tumors that have progressed after standard treatments. Researchers want to see how safe DCSZ11 is, what side effects it might cause, and if it can shrink tumors. They will also look at how your body handles the drug. To join, you must be at least 18 years old and have a solid tumor that has progressed after prior therapy. The study is currently recruiting up to 320 participants, but its overall status is unclear.

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It involves two main parts: a dose escalation phase (Phase 1a) to find the right dose, and a dose expansion/optimization phase (Phase 1b) to further study safety and effectiveness. Up to 320 participants are planned.

What's involved

You will receive DCSZ11 as a single intravenous (IV) infusion on Day 1 of each 21-day cycle. The study will also involve assessments for side effects and tumor response.

Compensation

Not stated in the trial record.

Follow-up

The frequency and severity of side effects will be monitored for up to 3 years. Tumor response will be assessed for 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.